Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. per Mitra, A, Bancroft, E, Barbachano, Y, Page, E, Foster, C, Jameson, C, Mitchell, G, Lindeman, G, Stapleton, A, Suthers, G, Evans, D, Cruger, D, Blanco, I, Mercer, C, Kirk, J, Maehle, L, Hodgson, S, Walker, L, Izatt, L, Douglas, F, Tucker, K, Dorkins, H, Clowes, V, Male, A, Donaldson, A

The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine per Whitaker, H, Kote-Jarai, Z, Ross-Adams, H, Warren, A, Burge, J, George, A, Bancroft, E, Jhavar, S, Leongamornlert, D, Tymrakiewicz, M, Saunders, E, Page, E, Mitra, A, Mitchell, G, Lindeman, G, Evans, D, Blanco, I, Mercer, C, Rubinstein, W, Clowes, V, Douglas, F, Hodgson, S, Walker, L, Donaldson, A, Izatt, L, Dorkins, H, Male, A, Tucker, K, Stapleton, A, Lam, J, Kirk, J, Lilja, H, Easton, D, Cooper, C, Eeles, R, Neal, D